Corrigendum: Gene therapy approaches for equine osteoarthritis.

Summary

# Gene Therapy Approaches for Equine Osteoarthritis: Editorial Summary Gene therapy represents a potentially transformative approach to managing osteoarthritis (OA) in horses, moving beyond traditional symptom management towards biological modification of diseased joint tissue. McIlwraith's research group reviewed the current landscape of gene delivery systems—including viral vectors (adeno-associated viruses and adenoviruses) and non-viral methods—alongside their application to equine OA, examining how these platforms could theoretically halt or reverse cartilage degradation at the molecular level. The paper synthesised evidence on candidate therapeutic genes, such as those encoding anti-inflammatory cytokines and cartilage-protective factors, whilst critically evaluating the technical and regulatory hurdles facing clinical translation in equine medicine. For practitioners, this work contextualises emerging research that may eventually offer joint-specific treatments capable of modifying disease progression rather than merely masking clinical signs—though substantial development and safety validation remain necessary before such approaches become available in practice. Understanding these mechanisms and limitations is valuable for staying informed about the trajectory of regenerative orthopaedic medicine in equine patients.

Read the full abstract on PubMed

Key Findings

• •This is a corrigendum (correction) to a previously published review article on gene therapy approaches for equine osteoarthritis
• •The original article DOI 10.3389/fvets.2022.962898 contained information requiring correction or clarification

Conditions Studied

Tags